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Abstract Intraperitoneal (IP) chemotherapy is more effective
than systemic chemotherapy for treating advanced ovarian
cancer, but is typically associated with severe complications
due to high dose, frequent administration schedule, and use of
non-biocompatible excipients/delivery vehicles. Here, we de-
veloped paclitaxel (PTX)-loaded microspheres composed of
di-block copolymers of poly(ethylene glycol) and
poly(sebacic acid) (PEG-PSA) for safe and sustained IP che-
motherapy. PEG-PSA microspheres provided efficient load-
ing (∼13 % w/w) and prolonged release (∼13 days) of PTX. In
a murine ovarian cancer model, a single dose of IP PTX/PEG-
PSA particles effectively suppressed tumor growth for more
Ming Yang and Tao Yu contributed equally.
Electronic supplementary material The online version of this article
(doi:10.1007/s13346-013-0190-7) contains supplementary material,
which is available to authorized users.
M. Yang : T. Yu : J. Wood :Y.<Y. Wang
Department of Biomedical Engineering, Johns Hopkins University
School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205,
USA
B. C. Tang : S. K. Lai
Department of Chemical and Biomolecular Engineering, Johns
Hopkins University, 3400 N Charles Street, Baltimore, MD 21218,
USA
J. Fu
Department of Ophthalmology, The Wilmer Eye Institute, Johns
Hopkins University School of Medicine, 400 N Broadway,
Baltimore, MD 21287, USA
Q. Zeng :C.<M. Chuang : T.<C. Wu : C.<F. Hung
Department of Pathology, Johns Hopkins University School of
Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA
T.<C. Wu : C.<F. Hung
Department of Obstetrics and Gynecology, Johns Hopkins
University School of Medicine, 600 N. Wolfe Street, Baltimore,
MD 21287, USA
T.<C. Wu : C.<F. Hung : J. Hanes
Department of Oncology, Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University School of Medicine, 600 N. Wolfe
Street, Baltimore, MD 21287, USA
B. W. Simons
Department of Molecular and Comparative Pathobiology, Johns
Hopkins University School of Medicine, 1550 Orleans Street,
Baltimore, MD 21231, USA
J. Hanes
Center for Cancer Nanotechnology Excellence, Institute for
NanoBioTechnology, Johns Hopkins University, 3400 N Charles
Street, Baltimore, MD 21218, USA
M. Yang : T. Yu :Y.<Y. Wang :B. C. Tang : J. Fu : J. Hanes (*)
The Center for Nanomedicine, Johns Hopkins University School of
Medicine, 400 N Broadway, Baltimore, MD 21287, USA
e-mail: hanes@jhu.edu
Present Address:
B. C. Tang
Koch Institute for Integrated Cancer Research, Massachusetts
Institute of Technology, 77 Massachusetts Ave, Cambridge,
MA 02139, USA
Present Address:
S. K. Lai
Eshelman School of Pharmacy, University of North Carolina at
Chapel Hill, Campus Box 7362, Chapel Hill, NC 27599, USA
Drug Deliv. and Transl. Res. (2014) 4:203–209
DOI 10.1007/s13346-013-0190-7
than 40 days and extended the median survival time to 75 days
compared to treatments with Taxol® (47 days) or IP placebo
particles (34 days). IP PTX/PEG-PSAwas well tolerated with
only minimal to mild inflammation. Our findings support
PTX/PEG-PSA microspheres as a promising drug delivery
platform for IP therapy of ovarian cancer and potentially other
metastatic peritoneal cancers.
Keywords Drug delivery . Controlled release .
Chemotherapy . Biodegradable polymers
Ovarian cancer is the fifth leading cause of death from malig-
nancies among women worldwide, with an estimated 275,100
deaths globally in 2011 [1]. It often remains clinically silent
until tumors have disseminated beyond the ovaries into the
peritoneal cavity, leaving patients with poor prognosis [2].
Intraperitoneal (IP) chemotherapy, which elevates peritoneal
drug concentrations, suppresses ovarian tumors more effec-
tively than conventional systemic treatment [3, 4].
Nevertheless, IP chemotherapy can lead to significant side
effects due to transient exposure to high levels of chemo drugs
and frequent injections [3–6]. In contrast, IP-controlled release
systems can maintain therapeutically effective yet moderate
levels of chemo in the peritoneal cavity to suppress tumors for
a prolonged period of time with reduced side effects [7–9].
While significant advances have been made in the develop-
ment of IP delivery systems [10–15], new platforms with
enhanced efficacy and biocompatibility are still needed. In
particular, systems with optimized particle size, surface prop-
erties, and degradation kinetics may provide greater particle
stability, reduced immunogenicity, and optimal clearance time
to improve particle-based IP chemotherapy [7–9].
Biodegradable polymers, including polyesters and
polyanhydrides, are widely used to develop drug delivery
systems that release therapeutic molecules in a sustained
fashion [16–18]. One of the advantages of polyanhydrides is
that they can be tailored to degrade at predictable rates and
release drug in a surface erosion-driven and tunable manner
[16, 19, 20]. A variety of polyanhydride-based copolymers,
such as poly (ether-anhydrides) [21–25] and poly (ester-
anhydrides) [26–31], have been developed and used for drug
delivery applications.
Here, we report the development of a microsphere-based
delivery system composed of poly(ethylene glycol)-co-
poly(sebacic acid) (PEG-PSA) for IP delivery of paclitaxel
(PTX) against ovarian cancer. PSA is a polyanhydride poly-
mer that has been widely studied and is used in Gliadel®
wafer, an FDA-approved product [16]. Since sustained release
of therapeutic molecules from polyanhydride particles occurs
concurrently with the erosion of particles, minimal residual
polymer is expected upon depletion of the drug. PEG, a
hydrophilic polyether polymer, has a demonstrated history
of safe use in FDA-approved pharmaceutical products [32].
During the synthesis of particles composed of PEG-
containing amphiphilic co-polymers, PEG partitions to the
particle surface, forming a dense coating that improves parti-
cle stability and reduces immunogenicity and thus improves
the biocompatibility of the particles [32–35].
We first formulated PTX-encapsulated PEG-PSA micro-
spheres (PTX/PEG-PSA) using an oil-in-water emulsion
method and characterized their physicochemical properties
in vitro. Detailed methods are provided in the Electronic
Supplementary Material online. All data represent mean ±
standard error of the mean (SEM) unless otherwise specified.
Scanning electron micrographs show that PTX/PEG-PSA
particles possessed smooth surfaces without drug precipitates
(Fig. 1a). The mean diameter of PTX/PEG-PSA particles
measured by a Coulter Multisizer was 14.2 μm with a
standard deviation of 5.8 μm (Fig. 1b). Submicron
particles (e.g., <1 μm) smaller than the openings of
peritoneal lymphatic ducts may be cleared rapidly by lym-
phatic drainage [7, 8]; thus, the relatively large size of PTX/
PEG-PSA particles may facilitate particle retention in the
peritoneal cavity.
We next tested three different target loading levels of PTX
to optimize the drug loading in PEG-PSA particles (Table 1).
At a target loading of 20 %, we achieved an optimal PTX
loading of 13±1 %with 67±6 % encapsulation efficiency. We
further characterized the release of encapsulated PTX from
PEG-PSA particles in vitro. As shown on Fig. 1c, PTX was
released from PEG-PSA particles for more than 2 weeks with
limited burst effects. Further tuning of drug loading and drug
release kinetics may be achieved by adjusting the molecular
weight and/or hydrophobicity of the polymer [23]. While the
system described here is engineered for IP delivery of PTX,
we have previously shown that PEG-PSA particles can effi-
ciently encapsulate and provide sustained release of other
molecules, such as etoposide [25]. PEG-PSA particles may
also be suitable for various types of peritoneal indications
other than ovarian cancer, including metastatic cancers in the
peritoneal cavity such as pancreatic cancer and peritoneal
inflammation such as gastroenteritis.
We next investigated the in vivo release of PTX/PEG-PSA
particles injected into the mouse peritoneal cavity. Residual
PTX was recovered at different time points by performing a
peritoneal lavage using PBS and then quantified by high
performance liquid chromatography. Figure 1d shows that
Taxol® (the clinical formulation of PTX) was quickly cleared
from the peritoneal cavity, with only 14 % of the initial dose
recovered by 2 h and no detectable drug level by 24 h. In
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contrast, ∼50 % of the initial dose delivered by PTX/PEG-
PSA particles remained in the peritoneal cavity at 24 h and
∼8 % was recovered on day 13. The drug retention profile of
PTX/PEG-PSA particles in vivo was consistent with the
in vitro release kinetics, implying that particles were largely
stable and cleared minimally from the peritoneal cavity. The
improved pharmacokinetics of PTX delivered by PEG-PSA
microspheres demonstrates the advantage of this particle sys-
tem for sustained IP drug delivery.
We also measured plasma drug concentrations at
predefined time points following treatment (Table 2). In mice
receiving 20 mg/kg IP Taxol®, plasma levels of PTX were
high (5.2±0.4 μg/mL) at 2 h after treatment and then declined
to 1.9±0.3 μg/mL at 4 h consistent with the documented rapid
clearance of Taxol® from the peritoneal cavity into systemic
circulation [36]. The half-life of IP Taxol® is
leading to a rapid decline in plasma PTX concentration to
leading to prolonged systemic exposure to PTX but at rela-
tively low levels.
We then evaluated the efficacy of IP PTX/PEG-PSA parti-
cles in a previously established murine ovarian tumor model
using luciferase-expressing mouse ovarian surface epithelial
cells (MOSEC-luc), which allows us to evaluate tumor burden
and, thus, the efficacy of new therapies in a noninvasive yet
quantitative fashion via bioluminescence measurements [37,
38]. Female C57BL/6 mice were inoculated intraperitoneally
with the MOSEC-luc cells. About 4 weeks later, tumor-
bearing mice were treated by IP administration of a single
dose of PTX/PEG-PSA particles (20 mg/kg), Taxol®
(20 mg/kg), or placebo PEG-PSA particles. Only mice receiv-
ing Taxol® showed signs of distress immediately upon ad-
ministration, likely due to the anaphylactic effects of excipi-
ents such as Cremophor EL® in Taxol®. As shown in Fig. 2a,
tumors in mice receiving IP placebo particles grew steadily,
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Fig. 1 In vitro and in vivo
characterizations of PTX/PEG-
PSA particles. a Scanning
electron micrograph, b volume-
weighted size distribution, and c
in vitro release kinetics for PTX/
PEG-PSA particles. d
Intraperitoneal retention of PTX
delivered by Taxol® or PTX/
PEG-PSA particles. Data
represent mean ± SEM (n=3).
Asterisk indicates statistical
differences at all time points
(p<0.05)
Table 1 Drug loading and en-
capsulation efficiency of PTX/
PEG-PSA particles
Target loading (% w/w) Actual loading (% w/w) Encapsulation efficiency (%)
10 7±1 74±3
20 13±1 67±6
30 13±1 43±5
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∼0.1 μg/mL at 30 h following IP Taxol® injection at 18mg/kg
[36]. In comparison, the plasma level of PTX in mice receiv-
ing IP PTX/PEG-PSA remained relatively constant at ∼1 μg/
mL from day 1 up to day 14, suggesting the microspheres
provided sustained release of PTXwithin the peritoneal cavity
∼3 h in mice,
with total bioluminescence signal levels reaching 2×108 p/s
by day 34 posttreatment at which point the extremely high
tumor load necessitated humane sacrifice. IP Taxol® showed
suppression, albeit modest, of tumor growth compared to pla-
cebo particles after the first week posttreatment, with average
tumor load reaching 2×108 p/s by day 40. In contrast, IP
delivery of PTX/PEG-PSA particles effectively inhibited tumor
growth over an extended period of time compared to Taxol®
and placebo particles. By day 40, the total bioluminescence
signals for mice treated with IP PTX/PEG-PSA were still
comparable to initial signal levels at day 0 (1.3×107 p/s). The
median survival times of mice receiving placebo and Taxol®
were only 34 and 47 days, respectively, with 0 % survival on
day 60 for both groups (Fig. 2b). In contrast, mice receiving
PTX/PEG-PSA particles demonstrated a median survival time
of >75 days, with all mice surviving at day 60 (Fig. 2b).
Finally, we evaluated the biocompatibility of IP PTX/PEG-
PSA particles. No morphologic anomalies were noted in the
major peritoneal organs of mice receiving IP Taxol®, PTX/
PEG-PSA particles, or PBS on days 1, 10, and 30 following a
single dose administered on day 0. For all groups, minimal to
mild inflammatory infiltrates were found in the mesentery but
not in other major organs (Fig. 3a). Average pathology scores
associated with PTX/PEG-PSA treatment (1.67, 1.29, and
1.00 on days 1, 10, and 30, respectively) were lower than
those for Taxol® (2.00, 1.71, and 1.69 on days 1, 10, and 30,
respectively), with complete return to baseline by day 30
(Fig. 3b). Total peritoneal leukocyte counts for both treatment
groups did not increase significantly at any time point com-
pared to the PBS control (Fig. 3c). However, the fraction of
neutrophils increased slightly after 1 day in both treatment
groups likely due to immediate exposure to PTX, but recov-
ered after 10 and 30 days (Fig. 3d). Throughout the entire
course of the study, no signs of gastrointestinal toxicity, such
as emesis, diarrhea, or significant weight loss, were observed
Table 2 Plasma PTX concentrations following IP Taxol® or PTX/PEG-
PSA
Treatment Time Plasma PTX concentration (μg/mL)
Taxol® 5 min 0
1 h 3.2±0.6
2 h 5.2±0.4
4 h 1.9±0.3
PTX/PEG-PSA 1 day 0.9±0.1
7 days 1.2±0.1
14 days 1.1±0.1
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Fig. 2 In vivo efficacy of IP delivered PTX/PEG-PSA microspheres,
Taxol®, or blank PEG-PSA microspheres in mice bearing IP MOSEC-
luc tumors. a Bioluminescence signals from MOSEC-luc tumors. PTX/
PEG-PSA particles better suppressed tumor growth than other treatments.
Double asterisks indicate statistical difference between PTX/PEG-PSA
and other groups starting from day 19 (p<0.01). bKaplan-Meier survival
curves. PTX/PEG-PSA particles significantly extended animal survival
to >75 days compared to blank PEG-PSA particles (34 days) and Taxol®
(47 days). Single asterisk indicates statistical difference between PTX/
PEG-PSA and other groups (p<0.05). cRepresentative bioluminescence
images of IP tumor burden. Data represent mean ± SEM (n=5 per
treatment set)
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in any of the treatment groups. These results demonstrate that
IP therapy using PTX/PEG-PSA particles was well tolerated,
with superior local biocompatibility to that of Taxol®.
The overall PTXdose administered in this study (20mg/kg)
is equivalent to ∼60 mg/m2 in humans [39], which is consis-
tent with the single IP Taxol® dose used previously in a
pivotal clinical trial [4]. However, IP Taxol® is commonly
combined with intravenous or IP platinum-based chemother-
apy (cisplatin or carboplatin) in the clinic, and treatments are
often given once every 3 weeks for six cycles [4], which
significantly increases overall systemic exposure to chemo-
therapeutic drugs and likely leads to severe systemic side
effects including myelotoxicity. Since PTX/PEG-PSA parti-
cles showedmarkedly higher efficacy than free PTX treatment
in our studies, we expect that PTX/PEG-PSA particles may be
used at a lower dose and dosing frequency to achieve similar
or greater efficacy than the current standard IP Taxol® treat-
ment. In addition, our results suggest that PTX is released
from PTX/PEG-PSA particles in a sustained fashion in the
peritoneal cavity and gradually absorbed into the systemic
circulation, leading to a sustained but relatively low level of
plasma PTX. Thus, we anticipate a lower incidence and lower
severity of systemic toxicity due to PTX/PEG-PSA treatment
compared to that caused by current standard IP chemotherapy.
Our results show that IP PTX/PEG-PSA significantly sup-
pressed the growth of ovarian tumors compared to standard
Taxol® treatment with better biocompatibility. The substantial
improvement in efficacy is likely due to the improved phar-
macokinetics of PTX in the peritoneal cavity when delivered
in PEG-PSA particles. Upon IP administration, Taxol® was
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Fig. 3 Toxicity associated with IP Taxol® and PTX/PEG-PSA particles.
aRepresentative histological images of mesenteric inflammatory cells for
each treatment and time point. PBS (A), Taxol (B, D, F), and PTX/PEG-
PSA (C, E,G) treatment groups are shown at day 1 (A, B,C), day 10 (D, E),
and day 30 (F, G) posttreatment. Arrows indicate groups of inflammatory
cells. Scale bars are 100 μm. b Pathology scores of representative hema-
toxylin and eosin-stained tissue sections of abdominal organs from mice
receiving Taxol® or PTX/PEG-PSA particles. Dashed line represents the
baseline score of PBS-treated mice. c Total leukocyte count from perito-
neal lavage samples. No significant differences were noted between
groups (p>0.05). d Relative proportion of different leukocytes in the
peritoneal lavage samples from mice receiving Taxol® or PTX/PEG-
PSA particles. Data represent mean ± SEM (n≥4 per treatment set)
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cleared by systemic absorption within hours (Fig. 1d). In
contrast, the PTX/PEG-PSA microspheres may effectively
avoid systemic drainage and last for weeks. Additionally,
PEG molecules present on particle surfaces can shield the
particles from biological constituents and immune cells in
the peritoneal cavity, minimizing particle aggregation and
immune elimination. Compared to irritating excipients such
as Cremophor EL and ethanol in Taxol®, the components of
PEG-PSA microspheres are more biocompatible and less
agitating. Overall, PTX/PEG-PSA particles may persist stably
and continuously release PTX in the peritoneal cavity, expos-
ing tumors to elevated levels of PTX over longer periods of
time with minimal side effects.
In summary, we developed a PEG-PSA-based microsphere
delivery system for sustained IP chemotherapy with PTX. We
demonstrated that PTX/PEG-PSA particles provided
sustained released of PTX in vitro and retention of PTX in
the peritoneal cavity over 2 weeks. In a murine model of
metastatic ovarian cancer, we demonstrated superior tumor
suppression by IP PTX/PEG-PSA particles compared to
Taxol®. We also showed that IP PTX/PEG-PSA particles
were well tolerated in vivo. The sustained release properties
and improved biosafety of PTX/PEG-PSA microspheres may
further advance IP chemotherapy for ovarian cancer and po-
tentially other metastatic peritoneal cancers.
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